PARSITAN 50 50 MG
ETHOPROPAZINE (ETHOPROPAZINE HYDROCHLORIDE) : 50 MG · DIN 01927744 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is PARSITAN 50?
PARSITAN 50 50 MG contains ETHOPROPAZINE (ETHOPROPAZINE HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 01927744, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PARSITAN 50 used for?
In the symptomatic treatment of drug-induced extrapyramidal reactions and of the manifestations (rigidity, akinesia, sialorrhea, oculogyric crisis, tremor, etc.) of Parkinson's disease of encephalitic, arteriosclerotic or idiopathic origin.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01927744 |
|---|---|
| Brand name | PARSITAN 50 |
| Generic / active ingredient | ETHOPROPAZINE (ETHOPROPAZINE HYDROCHLORIDE) : 50 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04AA05 PROFENAMINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Oct-2022 |
How is it administered?
Individualized. Drug-induced reactions: 100 mg b.i.d. Parkinsonism: Start 50 mg t.i.d., increase by 50-100 mg daily every 2-3 days. Normal range 100-500 mg/day (up to 1g+).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
bottles of 100
Contraindications
Glaucoma and hypersensitivity to phenothiazine drugs.
Warnings and precautions
Use with great caution in patients with prostatic hypertrophy, pyloric stenosis, or cardiovascular diseases. Monitor for blood dyscrasias during protracted high-dose therapy.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.